Inhibitor

(redirected from C1 inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Legal, Wikipedia.

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
References in periodicals archive ?
Klasik siniflamalar icinde gecen AE formlari arasinda; idiyopatik AE (IAE), allerjik AE (AAE), C1 inhibitor proteininin eksikligi veya disfonksiyonuna bagli olarak gorulen EAE ve klasik HAE (tip 1 ve tip 2), HAE tip 3 (idiyopatik, ostrogenle veya faktor 12 mutasyonuyla iliskili) ile steroid disi antiinflamatif ilaclar (SDAII) ve ADE inhibitorleri gibi belirli ilac reaksiyonlariyla iliskili olarak gorulen AE tablolari bulunmaktadir (1,3,4).
There may also be a role for icatibant in the management of patients with type 3 HAE where C1 inhibitor levels are normal (14).
Pharming spokesperson Marjolein van Helmond said that in the modified rabbits, each litre contains 12 grams of human C1 inhibitor.
kromozomun uzun kolunda lokalize olan C1 inhibitor geninde olusan heterozigot defekte bagli oldugu bildirilmistir.
The first oral presentation was titled Clinical Efficacy of Recombinant Human C1 Inhibitor in Patients with Acute Hereditary Angioedema Attacks (A.
These data demonstrate that patients who received prophylaxis with C1 inhibitor had significantly better quality of life compared to acute therapy with C1 inhibitor while on placebo," commented Dr.
The abstract Clinical Efficacy of Recombinant Human C1 Inhibitor in North American Patients with Acute Hereditary Angioedema Attacks (R.
6, 2013 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced it will present data relating to the quality of life in patients with Hereditary Angioedema (HAE) receiving nanofiltered C1 Inhibitor (C1 INH-nf) replacement therapy for prophylaxis as well as data relating to the Angioedema Clinical Epidemiology Testing Initiative for the study of Hereditary Angioedema (ACET) at the 70th American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting.
NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that new data from open-label studies evaluating the efficacy and safety of the investigational drug RHUCIN([R]) (recombinant human C1 inhibitor) for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE) were presented at the 7th C1 Inhibitor Deficiency Workshop on May 20 - 22, 2011 in Budapest, Hungary.
RUCONESTA (INN conestat alfa) is a recombinant version of the human protein C1 inhibitor (C1INH).
The poster, Clinical outcomes with recombinant human C1 inhibitor in the repeat treatment of acute attacks of hereditary angioedema in North American patients (B Zuraw, et al), summarizes an open-label clinical study that was conducted to assess the safety and efficacy of RHUCIN in the repeat treatment of acute attacks of HAE in abdominal, peripheral, oro-facial-pharyngeal and/or laryngeal and genito-urinary anatomical locations.